Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection

摘要: West Nile Virus (WNV) is endemic in Israel and a significant level of antibodies present the population due to natural exposure. Anecdotal cases suggested that presence anti-WNV intravenous immunoglobulin (IVIG) from Israeli donors (IVIG-IL) assisted recovery patients with severe WNV infection. To enhance therapeutic efficacy IVIG-IL against infection, OMRIX Biopharmaceuticals, Israel, have developed strategy for selection plasma units 10% fraction blood antibodies. Positive were processed into pharmaceutical grade IVIG (WNIG). Following inoculation WNV, mice received i.p. injections different doses (0.01–8 mg/mouse) or WNIG, according specific experimental protocol. WNIG was about 10 times more potent (per gr IgG) than regular when tested by ELISA neutralization assays. In mouse lethal infection model, prophylactic treatment at least 5–10-fold as compared IVIG-IL. Treatment during active encephalitis, three four days following had protective effect. also very effective protecting immunosuppressed mice. Indeed, dexamethasone-immunosuppressed 0.2 1.0 mg 4 h after virus led 100% survival. produced selected donated regions can be used produce superior activity measures.